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Abstract
Background: Optimal extent of surgery remains controversial in types 2 and 3 adenocarcinoma of esophagogastric
junction (AEG). We aimed to determine whether the extended procedure including mediastinal lymphadenectomy
is essential in all patients with AEG by comparing prognosis and recurrence of proximal gastric adenocarcinoma
based on total gastrectomy with intra-abdominal lymphadenectomy.
Methods: The clinicopathologic characteristics of 672 patients (type 2: 90, type 3: 211, upper third of the stomach:
371 cases) who underwent curative total gastrectomy with lymphadenectomy between 2003 and 2009 were
reviewed.
Results: Recurrence was observed in 36.7, 16.1, and 16.1% of cases of type 2 AEG, type 3 AEG, and cancer of the
upper third of the stomach, respectively. The 5-year disease-free survival rates were 62.6, 82.5, and 84.6%, respectively.
Subgroup analysis revealed that in early cancers, there was no difference in survival between the groups (93.2 vs. 96.7
vs. 98.7%) but in advanced cancers, there was a difference (47.9 vs. 75.4 vs. 71.8%, P < 0.001). There was no survival
difference in stage 1 (97.5 vs. 98.7 vs. 98.3%), but, in stage 2, type 2 AEG had a worse prognosis (41.9 vs. 92.1 vs. 83.0%).
Types 2 and 3 advanced AEG had higher rates of locoregional recurrence, especially in the vicinity of the
esophagojejunostomy and mediastinal lymph nodes compared to proximal gastric cancer.
Conclusions: Total gastrectomy without mediastinal lymphadenectomy might produce favorable outcomes in early
AEG and acquisition of a greater length of proximal margin, and removal of mediastinal lymph nodes might be helpful
in advanced cancers.
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Background
Adenocarcinoma of the esophagogastric junction (AEG)
is associated with a poor prognosis, and its incidence
has rapidly increased in Western countries [1–4]. How-
ever, in the Far East including Korea, although the inci-
dence of adenocarcinoma in the upper third of the
stomach is gradually increasing, data of AEG are lacking
[5–8]. This may be due to the difficulty of defining the
esophagogastric junction (EGJ), as well as the scarcity of
the disease entity. AEG is defined as a tumor with an
epicenter within 5 cm of the EGJ, and Siewert et al. clas-
sified EGJ cancer based on an endoscopic finding into
type 1 (lower esophageal cancer), type 2 (true EGJ cancer),
and type 3 (subcardial cancer), and this classification is
still widely used [9].
While curative resection of the primary tumor and
regional lymph nodes is the mainstay of the treatment
of EGJ cancer, the extent of surgery is still controversial
especially for types 2 and 3 AEG. Siewert et al. insisted
that for patients with type 2 tumors, esophagectomy
offered no advantage over extended gastrectomy if an
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R0 resection can be achieved [3]. On the other hand,
several groups have reported the outcomes of surgical
approaches including transthoracic or transhiatal
esophagectomy, total gastrectomy, and proximal gas-
trectomy [10–12]. As each of these studies involved
mixed patient groups undergoing a variety of surgical
procedures and extents of lymphadenectomy, there are
of limited use for evaluating the dependence of the
prognosis and recurrence pattern of AEG on the spe-
cific procedure employed.
The aim of this study was to investigate the differences
in the prognosis and pattern of recurrence of types 2
and 3 AEG compared with adenocarcinoma in the upper
third of the stomach when employing the same operation
as for proximal gastric cancer (total gastrectomy with
intra-abdominal lymph node dissection), and to deter-
mine whether the extended procedure including medi-




This retrospective study adhered to the guidelines estab-
lished by the Declaration of Helsinki, and was approved
by the institutional review board of Asan Medical Center.
All patients who underwent curative total or extended
total gastrectomy with D1+ or D2 lymphadenectomy
based on gastric cancer for Siewert types 2 and 3 AEG at
Asan Medical Center from 2003 to 2009 were reviewed.
To compare the prognosis, patients who received the
same operative procedure for adenocarcinoma in the
upper third of the stomach during the same period were
also investigated. All patients achieved pathologically
cancer-free resection margin. Their medical records were
reviewed to determine clinicopathologic characteristics,
including age at operation, sex, tumor location, size, gross
appearance, differentiation, Lauren’s classification, depth
of invasion, number of metastatic and total harvested
lymph nodes, lymphovascular and/or perineural invasion,
adjuvant chemotherapy, and recurrence pattern. With
regard to tumor location, the endoscopic findings in all
of the patients were reviewed by the gastric surgeons
and an experienced gastroenterologist. Patients that
were excluded where those who had a suspicious meta-
static lymph node in the mediastinum on preoperative
examination, those who received prior chemo- or
radio-therapy or those with synchronous malignancy,
recurred or metastatic gastric cancers, tumors in the
remnant stomach, and those with less than 15 har-
vested lymph nodes, and Borrmann type 4 tumours.
From this initial pool, a total of 672 patients (301 AEG
and 371 adenocarcinomas in the upper third of the
stomach) were finally analyzed.
Follow-up
Patients were regularly followed up and the study protocol
included physical examination, blood tests, tumor
markers, esophagogastroduodenoscopy, and abdomino-
pelvic computed tomography. With regard to the site of
recurrence, the first site at presentation was the one docu-
mented. Patterns of recurrence were classified into locore-
gional, distant metastasis, and both. Follow-up was
continued until July 31, 2015 and the median period of
follow-up was 60.8 months (range, 3.0 to 136.7 months).
Histological evaluation
All surgical specimens were handled and examined ac-
cording to the guidelines of the Japanese Gastric Cancer
Association [13]. All histological slides were reviewed by
experienced gastrointestinal pathologists.
Depth of invasion and nodal staging were determined
according to the American Joint Committee on Cancer
(AJCC) staging manual 7th edition [14]. The diagnosis
of carcinoma was based on the modified Vienna classifi-
cation, and the histological type was determined
according to the World Health Organization (WHO)
classification [15, 16].
Statistical analysis
SPSS statistical software (version 12.0 for Windows,
Chicago IL, USA) was used for all statistical analyses.
The chi-squared test was used to assess the correlation
between tumor location and sex, depth of invasion, dif-
ferentiation, gross pattern, presence of lymphovascular/
perineural invasion, and recurrence pattern. The
Mann-Whitney U test was used to compare age, tumor
size, and number of metastatic and harvested lymph
nodes according to tumor location. Disease-free sur-
vival rate was calculated by the Kaplan-Meier method,
and a multivariable Cox regression model was used to
identify independent prognostic factors. Statistical sig-
nificance was set at P < 0.05.
Results
Clinicopathologic findings of patients
During the period, a total of 672 patients with Siewert
types 2 and 3 AEG and upper third of stomach cancer
were analyzed. Their median age at operation was
60 years and, of them, 488 were men and 184 were
women. Types 2 and 3 AEG and upper third cancers
were found in 90, 211, and 371 cases. The median tumor
size was 4.7 cm.
Three hundred ninety-five cases (58.8%) were
advanced cancers. Histologically, 402 cases (59.8%) had
undifferentiated histology, and the intestinal type in
Lauren’s classification was the most dominant. The median
number of harvested lymph nodes was 28 and stage 1
tumors were the greatest followed by stages 2 and 3.
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The median length of the proximal resection margin
was 2.0 cm. Lymphovascular invasion and perineural
invasion were identified in 30.8 and 26.0%, of the tumors,
respectively. About half of the patients received adjuvant
chemotherapy. The results are summarized in Table 1.
Comparison of clinicopathologic factors according to
tumor location
Compared to upper third cancer, AEG showed elderly
predominance, deeper invasion, and Borrmann type 2 or
3 on gross appearance. It was also strongly associated
with differentiated tumor, intestinal type, and shorter
proximal resection margin. Sex, tumor size, number of
metastatic and harvested lymph nodes, and presence of
lymphovascular and perineural invasion did not differ
according to tumor location (Table 2).
Comparison of prognostic factors and disease-free
survival according to tumor location
A univariate analysis in both AEG and upper third
adenocarcinoma revealed that T stage, N stage, and
presence of lymphovascular and perineural invasion
were significantly associated with disease-free survival.
However, in a multivariable analysis, only T stage, N
stage, and lymphovascular invasion remained prognostic
factors (Additional file 1: Table S1).
Recurrences were observed in 33 (36.7%), 34 (16.1%),
and 60 (16.1%) cases of types 2 and 3 and upper third
cancer, respectively. Kaplan-Meier curves were plotted
to evaluate differences in disease-free survival according
to tumor location. Type 2 AEG had a lower survival rate
than type 3 tumors and those in the upper third of the
stomach (P < 0.001). The 5-year disease-free survival
rates in Siewert types 2 and 3 and upper third cancers
were 62.6, 82.5, and 84.6%, respectively (Additional file 2:
Figure S1). When disease-free survival was analyzed by
depth of invasion, there were no differences in survival
based on tumor location among early cancers (93.2 vs.
96.7 vs. 98.7%, P = 0.158). However, among advanced
ones, there was statistically significant difference in
Table 1 Clinicopathologic characteristics of patients with
adenocarcinoma of the EGJ and the upper third of the stomach
Variable Value





Siewert 2 90 (13.4%)
Siewert 3 211 (31.4%)
Upper third 371 (55.2%)































Proximal resection margin, median (cm) 2.0 (0.1–10.5)
Lymphovascular invasion
Identified 207 (30.8%)
Not identified 464 (69.1%)
Table 1 Clinicopathologic characteristics of patients with
adenocarcinoma of the EGJ and the upper third of the stomach
(Continued)
Not evaluated 1 (0.1%)
Perineural invasion
Identified 175 (26.0%)
Not identified 483 (71.9%)
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survival (47.9 vs. 75.4 vs. 71.8%, P < 0.001) (Fig. 1). We
also analyzed the survival according to stage based on
the AJCC staging manual 7th edition. In stage 1, there
were again no differences in survival (97.5 vs. 98.7 vs.
98.3%, P = 0.825). However, in stage 2, type 2 AEG had
a lower survival rate than the other two groups (41.9
vs. 92.1 vs. 83.0%, P < 0.001). In stage 3, type 2 AEG
appeared to have a worse prognosis but the effect was
not statistically significant (32.8 vs. 48.9 vs. 45.2%,
P = 0.132) (Fig. 2).
Table 2 Comparison of clinicopathologic factors according to tumor location in patients with adenocarcinoma of the EGJ and the
upper third of the stomach
Variables Tumor location P value
Siewert 2 Siewert 3 Upper third
Age in years, mean 63.1 (±11.5) 59.6 (±11.3) 56.5 (±11.7) <0.001
Sex =0.232
Male 71 (78.9%) 156 (73.9%) 261 (70.4%)
Female 19 (21.1%) 55 (26.1%) 110 (29.6%)
Tumor size in cm 4.36 (±2.33) 4.74 (±2.36) 4.78 (±2.71) =0.365
Gross appearance =0.001
I 4 (4.4%) 3 (1.4%) 6 (1.6%)
IIa/IIb/IIc 26 (28.9%) 67 (31.8%) 169 (45.6%)
III 0 (0.0%) 2 (0.9%) 4 (1.1%)
B1 5 (5.6%) 8 (3.8%) 5 (1.3%)
B2/B3 55 (61.1%) 131 (62.1%) 187 (50.4%)
Differentiation =0.003
Differentiated 49 (54.4%) 90 (42.7%) 131 (35.3%)
Undifferentiated 41 (45.6%) 121 (57.3%) 240 (64.7%)
Lauren’s classificationa =0.002
Intestinal 60 (67.4%) 109 (51.7%) 164 (44.3%)
Diffuse 24 (27.0%) 77 (36.5%) 164 (44.3%)
Mixed 5 (5.6%) 25 (11.8%) 42 (11.4%)
T stage =0.001
T1 30 (33.4%) 72 (34.1%) 175 (47.1%)
T2 18 (20.0%) 36 (17.1%) 46 (12.4%)
T3 25 (27.8%) 74 (35.1%) 102 (27.5%)
T4a 15 (16.7%) 24 (11.4%) 41 (11.1%)
T4b 2 (2.1%) 5 (2.3%) 7 (1.9%)
No. of metastatic LNs 3.1 (±5.4) 2.1 (±3.9) 1.8 (±4.6) =0.064
No. of harvested LNs 27.6 (±10.7) 29.5 (±12.1) 30.7 (±12.3) =0.074
Stage =0.015
1 40 (44.4%) 95 (45.0%) 203 (54.7%)
2 21 (23.3%) 58 (27.5%) 100 (27.0%)
3 29 (32.3%) 58 (27.5%) 68 (18.3%)
Proximal margin, cm 0.75 (±0.66) 1.36 (±0.79) 3.41 (±1.95) <0.001
Lymphovascular invasiona =0.219
Present 34 (37.8%) 67 (31.9%) 106 (28.6%)
Not identified 56 (62.2%) 143 (68.1%) 265 (71.4%)
Perineural invasiona =0.748
Present 26 (29.9%) 53 (26.5%) 96 (25.9%)
Not identified 61 (70.1%) 147 (73.5%) 275 (74.1%)
aThese variables were missing from the pathology reports of some of the patients
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Comparison of recurrence patterns according to tumor
location
Distant metastasis including peritoneal seeding, paraaortic
lymph node metastasis, and hematogenous spread was the
most common routes of recurrence in all three types of
cancers. However, type 2 and 3 AEGs had a higher inci-
dence of locoregional recurrence than those in the upper
third (P = 0.006). On the other hand, relapse at a distant
site was more frequent in the tumors of the upper third of
the stomach (Table 3). In type 2 and 3 AEGs, the most
common locoregional recurrence sites were in the vicinity
of esophagojejunostomy site (27.3 and 14.7% of all recur-
rences, respectively) and the mediastinal lymph nodes (6.1
and 2.9% of all recurrences, respectively), whereas they
were in the celiac axis area in the upper third cancers. All
locoregional recurrence sites were observed among
advanced tumors and there was no local relapse among
the early cancers.
Discussion
The prevalence of AEG in East Asian countries is much
lower than that of tumors in the distal part of the stomach,
and Siewert types 2 and 3 consists of the majority of AEGs.
Moreover, the characteristics of AEG in the East have been
reported to differ from in the West [17–19]. Although
several previous studies have reported the surgical out-
comes of AEG, most large-scaled studies were per-
formed in the West and data from the East are
relatively rare. In addition, the data on the recurrence
patterns of AEG has a limitation that most studies re-
ported the prognosis of several groups who underwent
different extents of surgery [3, 20–22]. Despite some
prospective randomized studies documenting the need
for mediastinal lymph node dissection and transhiatal
esophagectomy, the optimal surgical procedure for
types 2 and 3 AEG has not been established [10, 12]
and it is yet to be determined whether an extended pro-
cedure is essential for early AEGs. Until 2009, our de-
partment had a strategy for AEG of total gastrectomy
with lymphadenectomy (plus, if necessary, combined
resection of adjacent organs) similar to the strategy for
primary proximal gastric cancer. This enabled us to
analyze the prognosis and recurrence patterns of the two
cancers based on the same operative procedure. To the
best of our knowledge, this is the first study to investigate
the prognosis of AEG compared to that of upper third
cancer following total gastrectomy with D1+ or D2 lymph
node dissection.
In many retrospective studies, AEGs were classified
based not on endoscopic findings but on review of the
postoperative specimens [1, 17, 18]. However, treatment
with formalin could have caused specimens to shrink,
and the size of tumors may have been overestimated or
the tumors misclassified. To minimize such possibilities,
we followed the proposal of Siewert’s classification based
on endoscopic view, and classified the tumors by a
Fig. 1 Disease-free survival curves in patients with adenocarcinoma of the EGJ and upper third of the stomach divided into early and advanced cancers
Fig. 2 Disease-free survival curves in patients with adenocarcinoma of the EGJ and upper third of the stomach according to TNM stage
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review performed by experienced gastric surgeons and a
gastroenterologist. In addition, a classification based on
endoscopic findings would be more useful in clinical
practice when identifying appropriate surgical strategies
for treating different types of AEGs preoperatively.
The results of the present study differed in some epi-
demiologic and clinicopatholgic characteristics from
other studies. Contrary to the previously reported
greater proportion of males in AEG type 2 than type 3
[18, 23], there was no difference in sex ratio between the
two types in this study. In addition, this study included a
higher proportion of early cancers and smaller tumor
size than other reports. This may be because of the
national surveillance system for gastric cancer based on
barium study or esophagogastroduodenoscopy that may
detect cancers at earlier stage.
Radical resection with lymphadenectomy is the pri-
mary modality in the treatment of AEG, and currently
transhiatal extended total gastrectomy is favored for type
2 AEG to remove probable metastatic lymph nodes in
the mediastinum. Although postoperative complication
rate of transhiatal resection is lower than that of the
transthoracic approach, it has been reported to exceed
30% [10, 12]. This study demonstrated that total gastrec-
tomy without mediastinal lymph node dissection could
produce favorable oncologic outcomes in early AEG
similar to those of primary upper third gastric cancer.
There was no case of locoregional recurrence including
the mediastinum, but two patients with T1N3 type 2
AEG experienced distant metastasis involving the liver
and the paraaortic lymph nodes, respectively. Also,
patients with stage 1 AEG had an excellent disease-free
survival rate that did not differ from that of proximal
gastric cancer. On the other hand, among the advanced
cancers, type 2 AEG had a significantly worse prognosis
than the other two types which had similar prognoses.
Two randomized controlled studies reported a 5-year
disease-free survival rates of 27.0~48.6% in a transhiatal
group and 35.8~39.0% in a transthoracic group.
Although it was not possible to compare these results
because of the differences in the proportion of TNM
stage between the groups, our survival rate of 47.9% in
advanced type 2 AEG was better without mediastinal
lymph node dissection.
In terms of recurrence, the tumors formed different
patterns depending on their location. The proportion of
locoregional recurrence was higher in type 2 and 3
AEGs than in upper third cancers, in which most recur-
rence involved distant metastasis. In type 2, in particular,
about 40% of patients who experienced relapse had a
local recurrence. This phenomenon may have resulted
from inadequate local surgical control including insuffi-
cient proximal resection margins and absence of medias-
tinal lymph node dissection. Yuichi et al. reported
recurrence rates of 44.4% in type 2 and 41.0% in type 3
AEG, which are markedly higher than in our results
[24]. As the patients enrolled in that study did not
receive adjuvant chemotherapy and the proportion of
advanced cancers was higher, it is difficult to compare
oncologic outcomes directly. However, it is remarkable
that contrary to our findings, they reported that distant
metastasis was dominant and local relapse was very rare.
The two studies used similar abdominal surgery protocols
based on total gastrectomy and abdominal lymphadenec-
tomy including D2 dissection, and the presence of medias-
tinal lymphadenectomy plus esophagectomy might cause
differences in the recurrence pattern. In addition, in both
the Dutch and Japanese studies, although total recurrence
rates were higher than in our case, the local recurrence
was lower [10, 12]. Based on these findings, efforts to
obtain an enough length of proximal resection margin and
to remove mediastinal lymph nodes to minimize local
relapse might be helpful in advanced type 2 and 3 AEGs.
However, more research is required to prove the prognos-
tic benefit of aggressive local treatment in AEG, because
about half of the patients with local relapse also had dis-
tant metastases at the same time.
Although this study has limitations including a retro-
spective design and single institution data, its findings
are valuable in as much they allow one to compare the
Table 3 Comparison of recurrence sites according to tumor location in patients with adenocarcinoma of the EGJ and the upper
third of the stomach
Recurrence Sites Tumor location P value
Siewert 2 Siewert 3 Upper third
Distant metastasis 20 (60.6%) 27 (79.4%) 55 (91.7%) =0.006
Locoregional 5 (15.2%) 4 (11.8%) 3 (5.0%)
Both 8 (24.2%) 3 (8.8%) 2 (3.3%)
Near anastomosis 9 5 0
Mediastinal lymph nodes 2 1 1
Around celiac axis 1 0 4
Others 1 1 0
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prognoses of AEGs and primary proximal gastric car-
cinomas following the same operative procedure, and
to compare their recurrence patterns. In addition, we
propose that it is worth considering a tailored strategy
that total gastrectomy without mediastinal lymphade-
nectomy might produce favorable outcome in early
AEG and, in advanced AEG, the acquisition of a greater
length of proximal margin with removal of mediastinal
lymph nodes might be helpful. A better controlled pro-
spective trial is required to prove the benefit of this
strategy.
Conclusions
Total gastrectomy with lymphadenectomy might pro-
duce favorable outcomes in early AEG and acquisition
of a greater length of proximal margin with removal of
mediastinal lymph nodes should be considered in
advanced cancers.
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